Schneider H J
Fortschr Med. 1995 Jun 10;113(16):250-2.
Since benign prostatic hyperplasia (BPH) is a very common and slowly progressive disease which requires surgical treatment in only one-third of those affected, surveillance of the condition on the basis of subjective symptoms is of considerable importance. For this reason, the WHO developed a prostate symptom score (WHO-PSS or I-PSS), which includes both irritative and obstructive symptoms, and which has become accepted all over the world. This score can be used both in investigative studies as a means of monitoring the efficacy of therapy, and as a very good instrument for patient management in the doctor's office.
由于良性前列腺增生（BPH）是一种非常常见且进展缓慢的疾病，仅三分之一的患者需要手术治疗，因此基于主观症状对病情进行监测具有相当重要的意义。出于这个原因，世界卫生组织制定了前列腺症状评分（WHO-PSS或I-PSS），该评分包括刺激性和梗阻性症状，并且已在全球范围内得到认可。这个评分既可以在调查研究中用于监测治疗效果，也可以作为医生办公室中患者管理的一个非常好的工具。
